First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing ...

The Svelte stent, designed to facilitate direct stenting and transradial access in percutaneous coronary intervention (PCI), did not differ significantly from metallic everolimus-eluting stents with ...

DUBLIN--(BUSINESS WIRE)--The "Global Coronary Stents Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Global Coronary Stents Market was valued at ...

Next-generation vascular stents can make cardiovascular therapies minimally invasive and vascular treatments safe and less ...

The latest and largest trial to compare durable-polymer versus biodegradable-polymer stents—this time in the setting of acute coronary syndromes—should convince the field once and for all that a ...

Reva Medical has returned, raising $45 million to complete its work in the historically difficult market of bioresorbable stents. The California-based outfit went through Chapter 11 bankruptcy ...

Please provide your email address to receive an email when new articles are posted on . There were small increases in target lesion failure and device thrombosis within 3 years with a bioresorbable ...

PARIS--(BUSINESS WIRE)--Arterial Remodeling Technologies (“ART”) announced today that it has disclosed impressive in vivo and in vitro data related to its bioresorbable stent platform—data that ...

First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing ...

According to MarketsandMarkets™, the Interventional Cardiology Devices Market is projected to grow from about USD 31.12 ...

The DynamX Bioadaptor — arguably the most original concept in coronary stent design to come along in 3 decades — demonstrated excellent safety and efficacy in a 12-month international, ...